Your browser doesn't support javascript.
loading
Management of Secondary Genomic Findings.
Katz, Alexander E; Nussbaum, Robert L; Solomon, Benjamin D; Rehm, Heidi L; Williams, Marc S; Biesecker, Leslie G.
Afiliação
  • Katz AE; Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. Electronic address: alexander.katz@nih.gov.
  • Nussbaum RL; Invitae Corporation, San Francisco, CA 94103, USA; Volunteer Clinical Faculty, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Solomon BD; Office of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
  • Rehm HL; Medical & Population Genetics Program and Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pathology, Harvard Medical School, Boston, MA 02114, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02142, USA.
  • Williams MS; Genomic Medicine Institute, Geisinger, Danville, PA 17822, USA.
  • Biesecker LG; Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Am J Hum Genet ; 107(1): 3-14, 2020 07 02.
Article em En | MEDLINE | ID: mdl-32619490
ABSTRACT
Secondary genomic findings are increasingly being returned to individuals as opportunistic screening results. A secondary finding offers the chance to identify and mitigate disease that may otherwise be unrecognized in an individual. As a form of screening, secondary findings must be considered differently from sequencing results in a diagnostic setting. For these reasons, clinicians should employ an evaluation and long-term management strategy that accounts for both the increased disease risk associated with a secondary finding and the lower positive predictive value of a screening result compared to an indication-based testing result. Here we describe an approach to the clinical evaluation and management of an individual who presents with a secondary finding. This approach enumerates five domains of evaluation-(1) medical history, (2) physical exam, (3) family history, (4) diagnostic phenotypic testing, and (5) variant correlation-through which a clinician can distinguish a molecular finding from a clinicomolecular diagnosis of genomic disease. With this framework, both geneticists and non-geneticist clinicians can optimize their ability to detect and mitigate genomic disease while avoiding the pitfalls of overdiagnosis. Our goal with this approach is to help clinicians translate secondary findings into meaningful recognition, treatment, and prevention of disease.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Genéticas Inatas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Genéticas Inatas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hum Genet Ano de publicação: 2020 Tipo de documento: Article